Daniel Maurus

5.5k total citations · 2 hit papers
9 papers, 856 citations indexed

About

Daniel Maurus is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Neurology. According to data from OpenAlex, Daniel Maurus has authored 9 papers receiving a total of 856 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 4 papers in Neurology. Recurrent topics in Daniel Maurus's work include Gastric Cancer Management and Outcomes (5 papers), Barrier Structure and Function Studies (4 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Daniel Maurus is often cited by papers focused on Gastric Cancer Management and Outcomes (5 papers), Barrier Structure and Function Studies (4 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Daniel Maurus collaborates with scholars based in Germany, United States and Ukraine. Daniel Maurus's co-authors include Uğur Şahin, Özlem Türeci, Hui Cai, Ann-Kathrin Wallisch, Philip R. Dormitzer, Kena A. Swanson, Bianca Sänger, Wei Chen, Alexander Muik and Ahsan M. Arozullah and has published in prestigious journals such as Science, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Daniel Maurus

9 papers receiving 845 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera

2021 333 citations Alexander Muik, Ann-Kathrin Wallisch et al. Science profile →
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

2021 244 citations Uğur Şahin, Ö. Türeci et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Maurus Germany	8	314	287	233	180	174	9	856
Julien Maurizio France	9	60 0.2×	74 0.3×	159 0.7×	288 1.6×	42 0.2×	10	930
Luisa Chocarro Spain	14	61 0.2×	111 0.4×	504 2.2×	134 0.7×	8 0.0×	35	742
Evgeny S. Egorov Russia	9	59 0.2×	55 0.2×	112 0.5×	314 1.7×	17 0.1×	10	726
Najmeh Alirezaie Canada	8	85 0.3×	66 0.2×	55 0.2×	183 1.0×	9 0.1×	10	506
S X Hu China	3	36 0.1×	53 0.2×	158 0.7×	162 0.9×	123 0.7×	7	504
James Monkman Australia	15	88 0.3×	108 0.4×	357 1.5×	301 1.7×	9 0.1×	41	770
C. Colin Brinkman United States	18	50 0.2×	34 0.1×	219 0.9×	215 1.2×	11 0.1×	27	740
Jonathan Digby‐Bell United Kingdom	5	46 0.1×	41 0.1×	97 0.4×	331 1.8×	5 0.0×	17	510
Tatsuro Murano Japan	13	10 0.0×	150 0.5×	237 1.0×	166 0.9×	11 0.1×	49	545
Jesse T. Davidson United States	13	20 0.1×	109 0.4×	416 1.8×	179 1.0×	9 0.1×	28	1.0k

Countries citing papers authored by Daniel Maurus

Since Specialization

Citations

This map shows the geographic impact of Daniel Maurus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Maurus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Maurus more than expected).

Fields of papers citing papers by Daniel Maurus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Maurus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Maurus. The network helps show where Daniel Maurus may publish in the future.

Co-authorship network of co-authors of Daniel Maurus

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Maurus. A scholar is included among the top collaborators of Daniel Maurus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Maurus. Daniel Maurus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Lordick, Florian, Peter Thuss‐Patience, Michael Bitzer, et al.. (2023). Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer. Journal of Cancer Research and Clinical Oncology. 149(9). 5937–5950. 13 indexed citations

Muik, Alexander, Ann-Kathrin Wallisch, Bianca Sänger, et al.. (2021). Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera. Science. 371(6534). 1152–1153. 333 indexed citations breakdown →

Şahin, Uğur, Ö. Türeci, Georgy M. Manikhas, et al.. (2021). FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Annals of Oncology. 32(5). 609–619. 244 indexed citations breakdown →

Türeci, Ö., Uğur Şahin, Henning Schulze‐Bergkamen, et al.. (2019). A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Annals of Oncology. 30(9). 1487–1495. 161 indexed citations

Şahin, Uğur, Özlem Türeci, Georgy M. Manikhas, et al.. (2019). Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial.. Journal of Clinical Oncology. 37(4_suppl). 16–16. 16 indexed citations

Moran, Diarmuid, Daniel Maurus, Christoph Rohde, & Ahsan M. Arozullah. (2018). Prevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples. Annals of Oncology. 29. viii32–viii32. 21 indexed citations

Schüler, Martin, Salah‐Eddin Al‐Batran, Zanete Zvirbule, et al.. (2017). Expression of Claudin 18.2 and HER2 in gastric, gastroesophageal junction, and esophageal cancers: Results from the FAST study.. Journal of Clinical Oncology. 35(15_suppl). 4038–4038. 7 indexed citations

Trarbach, Tanja, Martin Schüler, Zanete Zvirbule, et al.. (2014). Efficacy and Safety of Multiple Doses of Imab362 in Patients with Advanced Gastro-Esophageal Cancer: Results of a Phase Ii Study. Annals of Oncology. 25. iv218–iv218. 14 indexed citations

Hörnberg, Hanna, Daniel Maurus, Maarten Zwart, et al.. (2013). RNA-Binding Protein Hermes/RBPMS Inversely Affects Synapse Density and Axon Arbor Formation in Retinal Ganglion Cells In Vivo. Journal of Neuroscience. 33(25). 10384–10395. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact